1. Home
  2. REVB vs HAO Comparison

REVB vs HAO Comparison

Compare REVB & HAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • HAO
  • Stock Information
  • Founded
  • REVB 2020
  • HAO 2018
  • Country
  • REVB United States
  • HAO China
  • Employees
  • REVB N/A
  • HAO N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • HAO
  • Sector
  • REVB Health Care
  • HAO
  • Exchange
  • REVB Nasdaq
  • HAO NYSE
  • Market Cap
  • REVB 3.8M
  • HAO 4.2M
  • IPO Year
  • REVB N/A
  • HAO 2024
  • Fundamental
  • Price
  • REVB $2.38
  • HAO $1.35
  • Analyst Decision
  • REVB
  • HAO
  • Analyst Count
  • REVB 0
  • HAO 0
  • Target Price
  • REVB N/A
  • HAO N/A
  • AVG Volume (30 Days)
  • REVB 283.8K
  • HAO 25.8K
  • Earning Date
  • REVB 08-08-2025
  • HAO 08-08-2025
  • Dividend Yield
  • REVB N/A
  • HAO N/A
  • EPS Growth
  • REVB N/A
  • HAO N/A
  • EPS
  • REVB N/A
  • HAO 0.19
  • Revenue
  • REVB N/A
  • HAO $48,970,924.00
  • Revenue This Year
  • REVB N/A
  • HAO N/A
  • Revenue Next Year
  • REVB N/A
  • HAO N/A
  • P/E Ratio
  • REVB N/A
  • HAO $7.17
  • Revenue Growth
  • REVB N/A
  • HAO 15.04
  • 52 Week Low
  • REVB $2.11
  • HAO $0.84
  • 52 Week High
  • REVB $168.00
  • HAO $124.25
  • Technical
  • Relative Strength Index (RSI)
  • REVB 34.09
  • HAO 48.76
  • Support Level
  • REVB $2.97
  • HAO $1.26
  • Resistance Level
  • REVB $3.18
  • HAO $1.45
  • Average True Range (ATR)
  • REVB 0.22
  • HAO 0.08
  • MACD
  • REVB 0.05
  • HAO -0.00
  • Stochastic Oscillator
  • REVB 7.14
  • HAO 41.82

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About HAO HAOXI HEALTH TECHNOLOGY LTD

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Share on Social Networks: